COMPARE
Five Peptides, Five Positions on the Translational Gap
Same organizing question across every row: what does each peptide do, what is it approved for, and how far has the human evidence actually gone?
The short version
Reading five peptide profiles side by side is more useful than reading them one at a time, because the differences between them are exactly the point. Two of these compounds — semaglutide and tirzepatide — are backed by tens of thousands of trial participants and multiple regulatory approvals. Two more — tesamorelin and PT-141 — are approved, but each for one narrow, specific population. One, BPC-157, has not reached human-trial approval at all.
The table below lines up mechanism, regulatory status, and evidence maturity for all five. Read it as a map of where each compound sits on the translational gap, not a ranking of which is "best" — a peptide with a narrow approval isn't a lesser compound, it's a compound that has only been rigorously tested for one thing.
Mechanism and target
| Peptide | Receptor / target | What it engages |
|---|---|---|
| Semaglutide | GLP-1 receptor | One incretin hormone receptor; appetite and glucose regulation |
| Tirzepatide | GIP + GLP-1 receptors | Two incretin hormone receptors at once ("dual agonist") |
| Tesamorelin | GHRH receptor | Pituitary signal that triggers the body's own growth-hormone release |
| BPC-157 | VEGFR2 (angiogenesis) + others | Blood-vessel-growth signaling tied to tissue repair |
| PT-141 | MC4R (melanocortin) | Central brain circuits governing sexual desire |
Each compound engages a different biological system, which is part of why they don't compete with each other for the same use — they're grouped here for what they illustrate about the research process, not because they treat the same condition.
Regulatory status and approved use
| Peptide | FDA status | Approved for |
|---|---|---|
| Semaglutide | Approved (multiple indications) | Type 2 diabetes, chronic weight management, cardiovascular risk reduction, MASH |
| Tirzepatide | Approved (multiple indications) | Type 2 diabetes, chronic weight management, obstructive sleep apnea |
| Tesamorelin | Approved (single indication) | Excess visceral fat in HIV-associated lipodystrophy only |
| PT-141 | Approved (single indication, single population) | Acquired, generalized HSDD in premenopausal women only |
| BPC-157 | Not approved | No approved human indication; research use only |
The gap between "approved" and "approved for the use under discussion" is a common source of confusion in public conversations. Tesamorelin and PT-141 are FDA-approved medicines, but for populations and conditions much narrower than the broader conversation around them often implies [13][24][26].
Evidence maturity
| Peptide | Human evidence base | Trial scale |
|---|---|---|
| Semaglutide | Extensive; multiple outcome trials | Tens of thousands of participants across trials [1][2][3][4][7] |
| Tirzepatide | Extensive; multiple outcome and head-to-head trials | Thousands of participants across trials [1][9][10][11] |
| Tesamorelin | Established within its indication | Hundreds of participants across a focused trial program [12][14][16] |
| PT-141 | Established within its indication | Over 1,200 participants across pivotal Phase 3 trials [24][25] |
| BPC-157 | Minimal | As of the most recent review, only three small human pilot studies [17][18] |
This is the row that most directly answers the translational-gap question. Semaglutide and tirzepatide sit at one extreme, with dense, multi-indication trial programs. BPC-157 sits at the other, with a rodent literature that is genuinely large but a human literature that is genuinely small. Tesamorelin and PT-141 occupy the useful middle ground: solid, focused trial programs that support a real approval, without the breadth of the incretin-class evidence base.
Reading these five together
None of these compounds compete for the same clinical use, so this is not a head-to-head comparison in the way semaglutide and tirzepatide compare to each other. It is a comparison of five points on the same underlying question: how does a molecule get from a laboratory finding to something a regulator has reviewed and approved, and what does the distance traveled say about the weight a claim can carry?
A claim backed by a 17,604-person cardiovascular outcomes trial [3] and a claim backed by a two-person safety pilot [17] can both be true and accurately reported — but they carry very different amounts of evidentiary weight. A careful reader treats them differently. That is the habit this site is built to encourage. For the source list behind every figure on this page, see references.